# Sea Buckthorn Blood Lipids Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/sea-buckthorn-blood-lipids-randomized-trial-evidence-review
Category: evidence-review
Summary: Sea Buckthorn Blood Lipids Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass
Last reviewed: 2026-08-05
Reviewed by: Migaku Evidence Review
# Sea Buckthorn Blood Lipids Randomized Trial: What the Evidence Says

## Quick Answer

Sea Buckthorn Blood Lipids Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 observational study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| From Nutritional Profile to Circular Bioeconomy: A Review of Sea Buckthorn Oil and By-Product Valorization | narrative review | 3 | 2026-05-25 | 10.3390/foods15111873 |
| Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence | observational study | 3 | 2026-05-20 | 10.3389/fnut.2026.1801946 |

## What The Sources Report

- Current challenges include a lack of standardization in extraction methods, a limited mechanistic understanding of bioactive interactions, and insufficient clinical evidence to substantiate health claims. [Jiang Xiaojing (2026); evidence level 3]
- Although this concentration is notably lower than the 30-35% typically found in tropical oils such as palm or coconut oil, PA remains integral to the unique therapeutic efficacy of SBSO. [Jiang Xiaojing (2026); evidence level 3]
- This distinction helps explain why higher POA in cholesterol esters, phospholipids, or adipose tissue is often associated with hypertriglyceridemia, abdominal adiposity, insulin resistance, non-alcoholic fatty liver disease, and vascular risk, whereas some studies of free POA or specific phospholipid pools report associations with better insulin sensitivity or lower diabetes risk (-). [Destaillats Frédéric (2026); evidence level 3]
- The sections below organize the evidence by metabolic domain and emphasize the need to distinguish endogenous POA as a marker of lipogenesis from exogenous POA delivered in foods or supplements. [Destaillats Frédéric (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For sea buckthorn blood lipids randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Jiang Xiaojing (2026). From Nutritional Profile to Circular Bioeconomy: A Review of Sea Buckthorn Oil and By-Product Valorization. DOI: 10.3390/foods15111873. PMCID: PMC13256188. PMID: 42279660. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256188/
- Destaillats Frédéric (2026). Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. DOI: 10.3389/fnut.2026.1801946. PMCID: PMC13230081. PMID: 42245547. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13230081/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.